FDA Clears Hand-Held Test for Bordetella Pertussis
By LabMedica International staff writers Posted on 04 Jan 2015 |
The United States Food and Drug Administration (FDA) have cleared an accurate, easy-to-use molecular diagnostic assay for Bordetella Pertussis that employs a unique hand-held platform and requires no pre-extraction of DNA.
The incidence of whooping cough, the very contagious disease caused by B. pertussis attaching to cilia that line part of the upper respiratory tract, has risen over the last few years. Whooping cough can cause serious illness in children and adults, and is most dangerous for infants and babies. Quidel Corporation (San Diego, CA, USA), a developer and provider of new diagnostic solutions, has received the FDA clearance for its AmpliVue Bordetella Assay to detect B. pertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having a respiratory tract infection attributable to B. pertussis.
AmpliVue Bordetella is an easy-to-use, self-contained, disposable molecular diagnostic test with superb clinical accuracy. The assay requires no upfront extraction of DNA and generates the result in approximately 75 minutes. The AmpliVue platform is based on Quidel’s novel Helicase Dependent Amplification (HDA) technology that enables rapid nucleic acid amplification without a thermal cycler. So, like all FDA-cleared AmpliVue assays, AmpliVue Bordetella is CLIA-classified as moderately complex and does not require investment in expensive thermocycling equipment. This benefit, plus less laboratory space requirements, can significantly lower cost when adopting new molecular testing methods.
"We are pleased to receive 510(k) clearance for our AmpliVue Bordetella Assay—our 5th assay in the AmpliVue format. We've shown that we can harness our proprietary HDA technology to develop fast, accurate molecular diagnostic assays with a menu that matters to our customers," said Douglas Bryant, president and CEO of Quidel, "Longer-term, we intend to leverage this technology for other molecular diagnostic applications that will be appealing to significant market segments and potentially to public health agencies worldwide."
Quidel's novel AmpliVue platform now enables laboratories of all sizes to perform highly sensitive and specific molecular tests, and currently has FDA clearance for B. Pertussis, C. difficile, Group A Strep, Group B Strep, HSV1 and HSV2.
Related Links:
Quidel Corporation
The incidence of whooping cough, the very contagious disease caused by B. pertussis attaching to cilia that line part of the upper respiratory tract, has risen over the last few years. Whooping cough can cause serious illness in children and adults, and is most dangerous for infants and babies. Quidel Corporation (San Diego, CA, USA), a developer and provider of new diagnostic solutions, has received the FDA clearance for its AmpliVue Bordetella Assay to detect B. pertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having a respiratory tract infection attributable to B. pertussis.
AmpliVue Bordetella is an easy-to-use, self-contained, disposable molecular diagnostic test with superb clinical accuracy. The assay requires no upfront extraction of DNA and generates the result in approximately 75 minutes. The AmpliVue platform is based on Quidel’s novel Helicase Dependent Amplification (HDA) technology that enables rapid nucleic acid amplification without a thermal cycler. So, like all FDA-cleared AmpliVue assays, AmpliVue Bordetella is CLIA-classified as moderately complex and does not require investment in expensive thermocycling equipment. This benefit, plus less laboratory space requirements, can significantly lower cost when adopting new molecular testing methods.
"We are pleased to receive 510(k) clearance for our AmpliVue Bordetella Assay—our 5th assay in the AmpliVue format. We've shown that we can harness our proprietary HDA technology to develop fast, accurate molecular diagnostic assays with a menu that matters to our customers," said Douglas Bryant, president and CEO of Quidel, "Longer-term, we intend to leverage this technology for other molecular diagnostic applications that will be appealing to significant market segments and potentially to public health agencies worldwide."
Quidel's novel AmpliVue platform now enables laboratories of all sizes to perform highly sensitive and specific molecular tests, and currently has FDA clearance for B. Pertussis, C. difficile, Group A Strep, Group B Strep, HSV1 and HSV2.
Related Links:
Quidel Corporation
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia